TY - JOUR
T1 - Neuroprotective effect of benzylideneacetophenone derivative on the MPTP model of neurodegeneration in mice
AU - Kang, Jun Mo
AU - Jung, Jae Chul
AU - Kim, Heejeong
AU - Lim, Heena
AU - Jang, Soyong
AU - Oh, Seikwan
N1 - Funding Information:
This work was supported by the grant (20070301-034-026-007-04) from BioGreen 21 Program, Rural Development Administration, Republic of Korea.
PY - 2008/9
Y1 - 2008/9
N2 - In this study, we investigated the neuroprotective effect of a benzylideneacetophenone derivative, JC3, in a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD). C57BL/6 mice were treated with MPTP (30 mg/kg, i.p.) for 5 consecutive days. JC3 (10 mg/kg, i.p.) treatment was initiated 2 h after the first administration of MPTP and then at 24-h intervals for 3 consecutive days. The mice were sacrificed for analyses 7 days after the last MPTP injection. Immunohistochemistry and Western blot were used to determine the expression levels of tyrosine hydroxylase (TH), dopamine transporter (DAT), OX-42 (a marker of microglial activation), and glial fibrillary acid protein (GFAP, a marker of astrocyte activation) in the substantia nigra (SN) and striatum (ST). The results of these experiments demonstrated that JC3 restored the decreased TH-immunoreactivity (IR) and DAT and JC3 attenuated the increase in OX-42, GFAP, and COX-2 on the SN and ST on day 7 post-MPTP injection. These results suggest that JC3 can be a neuroprotective agent in an MPTP-induced model of PD.
AB - In this study, we investigated the neuroprotective effect of a benzylideneacetophenone derivative, JC3, in a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD). C57BL/6 mice were treated with MPTP (30 mg/kg, i.p.) for 5 consecutive days. JC3 (10 mg/kg, i.p.) treatment was initiated 2 h after the first administration of MPTP and then at 24-h intervals for 3 consecutive days. The mice were sacrificed for analyses 7 days after the last MPTP injection. Immunohistochemistry and Western blot were used to determine the expression levels of tyrosine hydroxylase (TH), dopamine transporter (DAT), OX-42 (a marker of microglial activation), and glial fibrillary acid protein (GFAP, a marker of astrocyte activation) in the substantia nigra (SN) and striatum (ST). The results of these experiments demonstrated that JC3 restored the decreased TH-immunoreactivity (IR) and DAT and JC3 attenuated the increase in OX-42, GFAP, and COX-2 on the SN and ST on day 7 post-MPTP injection. These results suggest that JC3 can be a neuroprotective agent in an MPTP-induced model of PD.
KW - Benzylideneacetophenone
KW - DAT
KW - GFAP
KW - MPTP
KW - OX42
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=52649158701&partnerID=8YFLogxK
U2 - 10.1007/s12272-001-1275-5
DO - 10.1007/s12272-001-1275-5
M3 - Article
C2 - 18806951
AN - SCOPUS:52649158701
SN - 0253-6269
VL - 31
SP - 1098
EP - 1107
JO - Archives of Pharmacal Research
JF - Archives of Pharmacal Research
IS - 9
ER -